Tretinoin:
what decades of trials show

The first controlled trial

Weiss and colleagues ran a 16-week, double-blind study in JAMA in 1988. Each person applied tretinoin to one forearm and vehicle cream to the other, and half also treated the face. Thirty people completed the study. Every forearm treated with tretinoin improved in photoaging, and none of the vehicle-treated forearms did. On the face, 14 of 15 people treated with tretinoin improved. Irritation was the main side effect.

Two years on the whole face

Kang and colleagues randomized 204 people to tretinoin emollient cream 0.05% or a vehicle cream, applied once a day to the whole face for up to two years. Tretinoin gave significantly greater improvement than placebo in fine and coarse wrinkling, mottled hyperpigmentation, lentigines, sallowness and the investigator’s global assessment (p<0.05). Microscopic review of skin biopsies found no increase in atypical cells. In a subset at three centers, a marker of new collagen production rose versus placebo at month 12 (p=0.0074).

What the pooled trials show

A 2025 meta-analysis pooled eight randomized, vehicle-controlled trials of tretinoin for photodamaged skin, with 1,361 adults and follow-up from 16 weeks to two years. Fine-wrinkle grading favored tretinoin: mean difference 0.41 (95% CI 0.23 to 0.59; p<0.001). Coarse wrinkling showed 0.25 (0.12 to 0.37). Patients’ own overall rating favored tretinoin by 0.27 (0.03 to 0.51). The authors also noted signs of publication bias for fine wrinkles.

Acne

A 2019 systematic review of 54 trials of US-approved topical retinoids, published 2008 to 2018, found that retinoids beat vehicle on acne outcomes. With benzoyl peroxide, 26.1% to 34.9% of people had an improved Investigator Global Assessment score at week 12, versus 7% to 11.8% on vehicle (p<0.001). Tretinoin and tazarotene did not differ significantly. The American Academy of Dermatology’s 2024 guideline gives topical retinoids a strong recommendation, alongside oral doxycycline.

Tolerability

The photoaging meta-analysis reported treatment-related adverse events in 492 of 822 tretinoin recipients, with an odds ratio of 3.14 (95% CI 1.82 to 5.42) against vehicle. Most of these were skin irritation, which patients rated themselves. The authors described tretinoin as safe, but the odds ratio says irritation is common, and the 2019 review found tretinoin 0.05% caused adverse events in 62% of patients, against 19% on adapalene 0.1%.

Melasma, and what we cannot quote

Tretinoin is also part of the triple combination used for melasma, with hydroquinone and a corticosteroid. The 2003 multicenter trial of that triple cream compared it with each of the dual combinations. At week 8, 26.1% of people on the triple cream had complete clearing of their melasma, versus 4.6% with the dual combinations (Taylor SC et al., Cutis 2003, PubMed 12889718). A 2024 meta-analysis of melasma treatments found cysteamine comparable to hydroquinone-based regimens and to modified Kligman’s formula (p=0.434), which suggests the triple cream is not the only route to a good result.

GHK-Cu, with care

Copper peptide (GHK-Cu) creams are sold for wrinkles. Human studies are small. A randomized trial of 40 women used a nano-carrier GHK-Cu serum for eight weeks, and reported wrinkle reductions compared with a vehicle serum. We could not retrieve the primary paper, so we quote none of its figures. Most of the evidence for GHK-Cu comes from cell and animal studies.

What this does not say

• The trials mostly used tretinoin 0.05% or 0.02% creams, applied to a defined area for weeks to two years. Compounded versions were not studied in them, and a different strength or base can behave differently.
• The photoaging trials were small, mostly US-based and industry-funded, and most lacked long-term follow-up. Wrinkle scales differed between trials.
• Results are averages. They do not predict how any one face will change, and they do not show that tretinoin reverses aging.
• The 2024 AAD guideline recommendation is for acne, not for photoaging. Irritation, dryness and peeling are the common reasons people stop.

Sources

1. 1.Weiss JS, Ellis CN, Headington JT, et al. Topical tretinoin improves photoaged skin: a double-blind vehicle-controlled study. JAMA 1988;259:527-32. JAMA
2. 2.Kang S, Bergfeld W, Gottlieb AB, et al. Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin: a two-year, randomized, placebo-controlled trial. Am J Clin Dermatol 2005;6(4):245-53. American Journal of Clinical Dermatology
3. 3.Olsen EA, Katz HI, Levine N, et al. Tretinoin emollient cream for photodamaged skin: results of 48-week, multicenter, double-blind studies. J Am Acad Dermatol 1997;37:217-26. Journal of the American Academy of Dermatology
4. 4.Huang HY, Lee LTJ. Tretinoin for photodamaged facial skin: systematic review and meta-analysis of randomized controlled trials. Dermatol Pract Concept 2025;15(4):e20255172. Dermatology Practical & Conceptual
5. 5.Kolli SS, Pecone D, Pona A, et al. Topical retinoids in acne vulgaris: a systematic review. Am J Clin Dermatol 2019;20(3):345-65. American Journal of Clinical Dermatology
6. 6.Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2024. Journal of the American Academy of Dermatology
7. 7.Wu BQ, Wang YJ, Chang CC, et al. Clinical efficacy of cysteamine application for melasma: a meta-analysis. J Clin Med 2024;13:7483. Journal of Clinical Medicine